מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
FOSLEVODOPA; FOSCARBIDOPA
ABBVIE CORPORATION
N04BA07
FOSLEVODOPA AND DECARBOXYLASE INHIBITOR
240MG; 12MG
SOLUTION
FOSLEVODOPA 240MG; FOSCARBIDOPA 12MG
SUBCUTANEOUS
15G/50G
Prescription
Active ingredient group (AIG) number: 0264641001; AHFS:
APPROVED
2023-05-03
_VYALEV (foslevodopa/foscarbidopa) _ _ _ _ _ _Page 1 of 53_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR VYALEV™ foslevodopa/foscarbidopa solution Solution, 240 mg/mL foslevodopa and 12 mg/mL foscarbidopa, subcutaneous infusion Antiparkinson Agent ATC Code: N04BA07 AbbVie Corporation 8401 Trans-Canada Highway St-Laurent, Qc H4S 1Z1 Date of Initial Authorization: MAY 03, 2023 Submission Control Number: 263826 _ _ _VYALEV (foslevodopa/foscarbidopa solution) _ _ _ _ _ _Page 2 of 53_ RECENT MAJOR LABEL CHANGES SECTION DATE None N/A TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 6 4.1 Dosing Considerations ............................................................................................ 6 4.2 Recommended Dose and Dosage Adjustment ....................................................... 6 4.4 Administration ....................................................... קרא את המסמך השלם